Pipeline › survodutide
survodutide
Not FDA-approved, and in phase 3 development, not authorised in the European Union. 6 active trials, the next due to complete 2027-11-30.
GLP-1/glucagon agonist, SC, from Boehringer Ingelheim / Zealand. Every figure below is taken directly from ClinicalTrials.gov, Drugs@FDA, the FDA Drug Shortage Database, the EMA register or Europe PMC, and re-checked every four hours.
- Status
- phase3
- Target
- GLP-1/glucagon
- Route
- SC
- Sponsor
- Boehringer Ingelheim / Zealand
- First FDA approval
- Not approved
- EU authorisation
- Not authorised
- Active trials
- 6 (5 in phase 3)
- Participants enrolled
- 5,310
- Trials with a reporting date
- 3
- Approved FDA submissions
- 0
Recent changes
| Detected | Change | Trial | Detail | Phase |
|---|---|---|---|---|
| 2026-09-30 | New trial registered | ELEVATE-LIVER: A Study to Test Whether Survodutide Helps Improve Heart Structure and Function in People With Overweight or Obesity and Fatty Liver Disease NCT07850063 · Boehringer Ingelheim | Not yet recruiting, n=600 | P3 |
| 2026-09-30 | New trial registered | SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight NCT07850050 · Boehringer Ingelheim | Not yet recruiting, n=600 | P3 |
When these trials report
Next 3 of 3 active trials by estimated primary completion.
| Est. completion | Trial | Sponsor | Phase | Participants |
|---|---|---|---|---|
| 2027-11-30 | Albuminuria Reduction Study With Survodutide Treatment in Kidney Disease NCT07206290 · Change in first morning void UACR | University Medical Center Groningen | P2 | 120 |
| 2028-01-17 | A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar NCT07754461 · Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41 | Boehringer Ingelheim | P3 | 600 |
| 2028-07-26 | SYNCHRONIZE®-HERA: A Study to Test Whether Survodutide Helps Women Who Are Living With Overweight or Obesity and Are Going Through or Have Finished Menopause, to Lose Weight NCT07850050 · Percentage change in body weight from baseline to Week 52 | Boehringer Ingelheim | P3 | 600 |
Indications under study
Chronic Kidney Disease; Liver Fibrosis; Metabolic Dysfunction Associated Steatohepatitis; Metabolic Dysfunction Associated Steatohepatitis (MASH); Metabolic Dysfunction-associated Steatotic Liver Disease; Obesity; Type 2 Diabetes.
Recent papers
| Published | Title | Journal |
|---|---|---|
| 2026-10-02 | Survodutide for the treatment of obesity: Mechanistic rationale, clinical evidence, and remaining uncertainties Sergi CM. | Contemp Clin Trials |
| 2026-10-01 | Nephroprotective Effects of the Dual GCGR/GLP-1R Agonist Survodutide in Hypertension-Accelerated Diabetic Kidney Disease Hamilton A, Thisted L, Ougaard M, Hahn M, Andersen K, Perens J, Augustin R, Bajrami B, Rist W, Christensen M, Hansen HH, Klein T. | Diabetes Obes Metab |
| 2026-10-01 | Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes Wharton S, le Roux CW, Startseva E, Kloer IM, Alhussein A, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Butt JH, Ekinci EI, Jastreboff AM, Ji L, Schou M, Tinahones FJ, Kokkinos AD, Merkely B, Ogawa W, Pedersen SD, Pietiläinen KH, Quinn D, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM, SYNCHRONIZE-2 Investigators. | N Engl J Med |
| 2026-08-25 | Author Correction: Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ, SYNCHRONIZE-MASLD Investigators. | Nat Med |
| 2026-08-14 | Survodutide for Obesity in Chinese Adults: Phase 3 Randomized Trial Design and Baseline Characteristics (SYNCHRONIZE™-CN) Ji L, Chen L, Cheng Z, Lu Y, Yang Y, Fu F, Zhu Y, Jin L, Kloer IM. | Diabetes Ther |
| 2026-08-03 | Weight reduction-dependent/-independent effects of survodutide on liver endpoints: Mediation analysis of a phase 2 trial in MASH Noureddin M, Sanyal AJ, Bedossa P, Fraessdorf M, Schoelch C, Startseva E, Marshall SR, Marshall SR, Alhussein A, Neff GW, Lawitz EJ, Lawitz EJ, Bugianesi E, Anstee QM, Newsome PN, Ratziu V, Hosseini-Tabatabaei A, Schattenberg JM, Alkhouri N, Younes R. | Hepatology |
| 2026-06-22 | Dual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity Ekinci EI, Maldonado SG, Unseld A, Martinez JA, Hennige AM, Schoelch C. | Diabetes Obes Metab |
| 2026-06-07 | Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial Kaplan LM, Startseva E, le Roux CW, Wharton S, Bozkurt B, Mazo DF, von Schlippenbach J, González Maldonado S, Ajaz Hussain S, Neff GW, Gonzalez Rojas Y, Smith C, Younes R, Sanyal AJ, SYNCHRONIZE-MASLD Investigators. | Nat Med |
| 2026-06-07 | Survodutide Once Weekly for the Treatment of Adults with Obesity le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdański P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietiläinen KH, Sattar N, Seufert J, Stenlöf K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM, SYNCHRONIZE-1 Investigators. | N Engl J Med |
| 2026-06-05 | How does survodutide work? Plain language review of a potential new medication for obesity and liver disease Almandoz JP, Miras AD, Seufert J, Paul E. | Ther Adv Gastroenterol |
| 2026-05-31 | Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE-JP Trial Yokote K, Yamauchi T, Fukushima Y, Takatsuka Y, Kato M, Yan S, Inoue T, Borowska L, Brueckmann M, Ogawa W, SYNCHRONIZE‐JP Trial Investigators. | Diabetes Obes Metab |
| 2026-03-19 | A review of survodutide: a new dual acting agonist Yathindra MR, Bhattacharjee A, Pundir N, Patel P, Jacob NE, Jossy PE, Seetharaman R. | Minerva Endocrinol (Torino) |
| 2026-02-04 | Optimization of patient and site engagement in the SYNCHRONIZE™ phase 3 clinical trial program for survodutide in obesity through clinical trial simulation Rubino DM, Mooney V, van de Walle V, Baanstra D, Daniëls W, Recaldin C, Nadglowski J. | Contemp Clin Trials Commun |
| 2026-02-02 | Survodutide acts through circumventricular organs in the brain and activates neuronal regions associated with appetite regulation Zimmermann T, Bleymehl K, Haebel P, Perens J, Roostalu U, Hecksher-Sørensen J, Doerr J, Jarosch S, Lam D, Klein H, Pekcec A, Chehimi SN, Crist RC, Reiner BC, Hayes MR, Augustin R. | Mol Metab |
| 2025-12-22 | Operationalising disease modification in obesity trials: A blueprint based on the SYNCHRONIZE-1 survodutide study Wang B, Huang J, Chen Z. | Diabetes Obes Metab |
Every survodutide trial on file
All 14 registered trials of survodutide, largest first. Each links to its own page and to the registry record.